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Abstract
The impact of vitamin D deﬁciency on the recovery of patients with malnutrition remains undeﬁned. Our aim was to study the
prevalence of vitamin D deﬁciency in a well-characterized cohort of patients with malnutrition and its association with outcomes.
Within this secondary analysis of a randomized controlled trial, we examined the association of vitamin D deﬁciency and adverse
clinical outcomes over a follow-up of 180 days in hospitalized patients at risk for malnutrition. We measured 25-hydroxyvitamin D
levels upon admission and deﬁned Vitamin D deﬁciency when levels were <50nmol/l. The primary endpoint was 180-day mortality.
The prevalence of vitamin D deﬁciency in our cohort of 828 patients was 58.2% (n=482). Patients with vitamin D deﬁciency had
increased 180-day mortality rates from 23.1% to 29.9% (odds ratio 1.42, 95% conﬁdence interval [CI] 1.03–1.94, P= .03). When
adjusting the analysis for demographics, comorbidities, and randomization, this association remained signiﬁcant for the subgroup of
patients not receiving vitamin D treatment (adjusted odds ratio 1.63, 95%CI 1.01–2.62, P= .04). There was no signiﬁcantly lower risk
for mortality in the subgroup of vitamin D deﬁcient patients receiving vitamin D treatment compared to not receiving treatment
(adjusted odds ratio 0.74, 95% CI 0.48–1.13, P= .15).
Vitamin D deﬁciency is highly prevalent in the population of malnourished inpatients and is negatively associated with long-term
mortality particularly when patients are not receiving vitamin D treatment. Our ﬁndings suggest that malnourished patients might
beneﬁt from vitamin D screening and treatment in case of deﬁciency.
Abbreviations: CI = conﬁdence interval, EFFORT = effect of early nutritional support on frailty, functional outcomes, and recovery
of malnourished medical inpatients trial, HR = hazard ratio, LOS = length of hospital stay, NRS = nutritional risk score, OR = odds
ratio, QoL = quality of life.
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1. Introduction
Vitamin D deﬁciency is common worldwide[1] and associated
with increased risks for cancer, cardiovascular and infectious
diseases, and mortality.[2–7] For this reason, international
societies including the Endocrine Society of the United States,
recommend prevention and treatment of vitamin D deﬁciency.
The required vitamin D levels are according to age groups
between 600 and 800IU/d. If patients are already vitamin D
deﬁcient, higher levels of vitamin D (50,000IU/week for 8 weeks)
are needed to correct vitamin D deﬁciency. This therapy is then
followed by a maintenance therapy of 1500 to 2000IU/d.[8]
Although there is ongoing discussion about the optimal vitamin
D serum level, there is general consensus that a 25-hydrox-
yvitamin D (25(OH)D) serum level of less than 50 nmol/L is
considered to be deﬁcient and levels lower than 25 nmol/L are
considered to be severely deﬁcient.[9]
Several pre-clinical and clinical studies have found vitamin D to
play a key role in different pathophysiological processes.
Cholecalciferol is produced in the human skin through the
transformation of 7-dehydrocholesterol by the action of UV B
radiation.Additionally to the endogenousproduction thatdepends
signiﬁcantly on sun exposure, diet can also contain vitamin D,
especially in food of animal origin.[10] VitaminD is metabolized in
the liver to 25(OH)D and later activated in the kidneys to 1.25-
dihydroxyvitamin (1.25(OH)2D). The activated form interacts
with more than 200 genes and strongly inﬂuences several cellular
processes, such as proliferation, differentiation, and apoptosis.
Angiogenesis, insulin and renin production as well as bone and
muscle metabolism are also inﬂuenced by 1.25(OH)2D.[11,12]
Several clinical studies have focus on the importance of vitamin
D in different patient populations also including hospitalized,
medical inpatients. A recently systematic review and meta-
analysis[13] investigated effects of vitamin D deﬁciency on adverse
medical outcomes across different medical inpatient populations.
While several observational studies reported vitamin D deﬁciency
to be highly prevalent inmedical inpatients and strongly associated
with different adverse outcomes, there were only few intervention
trials demonstrating that treatment with vitamin D can actually
lower the risk for these adverse outcomes. Yet, while most
identiﬁed studies have focused on healthy individuals or patients
with speciﬁc diseases, there is a lack of study data regarding the
population of severely ill and hospitalized patients with malnutri-
tion – a condition that puts patients at particular risk for adverse
clinical outcomes.[14,15]Understanding theprevalenceof vitaminD
deﬁciency and its associationwith outcome in this high-risk patient
population may help to design preventive strategies.
To close this gap, we conducted a secondary analysis of a
prospective trial including consecutive patients with malnutrition
upon hospital admission. Our aim was to study the prevalence of
vitamin D deﬁciency in this well-characterized cohort of patients
with malnutrition and its association with outcomes. We also
asked the question whether vitamin D treatment may reduce the
risks associated with vitamin D deﬁciency.
2. Methods
2.1. Study design and setting
This is a secondary analysis of the prospective effect of early
nutritional support on frailty, functional outcomes and recovery
of malnourished medical inpatients trial (EFFORT). EFFORT
was a pragmatic, investigator-initiated, open-label, multicentre
trial that was undertaken in 8 Swiss hospitals from April 2014 to
February 2018. The ethical committee of theNorthwestern part of
Switzerland (EKNZ; 2014_001) approved the study protocol and
all patients or their authorized representatives provided written
informed consent. The trial was registered at ClinicalTrials.gov
(https://clinicaltrials.gov/ct2/show/NCT02517476). Themain aim
of this trial was to assess the effects of early nutritional therapy on
patientoutcomes in themedical inpatients setting.The rationale for
the trial, design details, and eligibility features have been published
previously[16] as have the main results of the trial.[17]
2.2. Patient population and management
EFFORT enrolled consecutive patients at nutritional risk (deﬁned
by a nutritional risk score [NRS] ≥3 points) with an expected
lengthofhospital stay (LOS)≥5days if theywerewilling toprovide
informed consent. NRS includes assessment of the patient’s
nutritional status, which is based on weight loss, body mass index
and general condition or food intake and disease severity (stress
metabolism), and is associated with higher risk for adverse
outcomes.[18,19] Each part is scored from0 to3 points, and patients
receive an extra point for age above 70 years. Patients were
excluded if initially admitted to intensive care units or surgical
units, unable to ingest oral nutrition, already receiving nutritional
support on admission, with a terminal condition (ie, end-of-life
situation), hospitalized because of anorexia nervosa, acute pan-
creatitis, acute liver failure, cystic ﬁbrosis or stem cell transplanta-
tion, after gastric bypass surgery, or with contraindications for
nutritional support, and patients previously included in the trial.
While EFFORT included a total of 2028 patients, this
secondary analysis focuses only on the 828 patients, where
vitamin D was measured as part of the clinical routine, and we
excluded the 1200 patients with no vitamin D measurement (see
Appendix Table 5, http://links.lww.com/MD/D406 for compari-
son of patients with and without Vitamin D measurement).
Upon admission, medical diagnosis according to International
Statistical Classiﬁcation of Disease and Related Health Problems
10th Revision (ICD) 10-codes, socio-demographic and anthro-
pometric data, baseline muscle strength, and functional status
using Barthel index was assessed in all patients based on the trial
protocol. We also had a detailed history regarding vitamin D
supplementation before hospital admission. After discharge,
blinded study nurses contacted the patients after 30 and 180 days
for a structured telephone interview. Different health-related
outcomes and treatment history regarding vitamin D were
systematically assessed at these time points.
2.3. Patient groups and endpoints
We classiﬁed patients based on their initial vitamin D level into
vitamin D “deﬁcient” (<50 nmol/L) and “not deﬁcient” (≥50
nmol/L). Furthermore, patients were divided into “treated” and
“untreated” groups for the statistical calculations (Fig. 1). For
vitamin D measurement, we used a chemiluminescence immuno-
assay called IDS-iSYS 25-OH-Vitamin.[20] This assay detects 25
(OH)D2 as well as 25(OH)D3.
Some patients had vitamin D supplementation upon hospital
admission, mostly prescribed by their general practitioner or
from a previous hospitalization and some patients were started
on treatment during the index hospital stay. We thus classiﬁed
patients as receiving vitamin D treatment (“treated patients”) if
they received vitamin D supplementation before, during or after
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the index hospital stay and the “untreated” patients were those
not receiving any kind of supplementation at any time.
The primary endpoint of this analysis is all-cause mortality
within a follow-up of 180-days. Complete 180-day follow-up
data were available in 95.2%. For the 4 patients lost to follow up,
data carry forward from day 30 was used.
Secondary endpoints included mortality at 30-days, LOS, and
functional outcomes including Barthel index decline and quality
of life (QoL) each measured at 30 and 180 days.
Barthel index[17] measures performance in activities of daily
living and comprises 2 groups of items, 1 related to self-care
(feeding, grooming, bathing, dressing, bowel and bladder care,
and toilet use), the other related to mobility (ambulation,
transfers, and stair climbing). We used the German translation
which has a score ranging from 100 to 0 with lower scores
indicating more severe disability. Decline is deﬁned as Barthel
index reduction of 10% or more from admission.
QoL assessment is using the EuroQol group 5-dimension self-
report questionnaire.[21] This included the European quality of
life 5 dimensions index (values range from 0 to 1, with higher
scores indicating better life quality) and the visual analog scale
(EQ-5D VAS) (scores range from 0 to 100, with higher scores
indicating better health status).
2.4. Statistical analysis
Patient characteristic continuous variables are expressed as
medians (interquartile ranges, 25th–75th percentiles), while
frequencies are reported as percentages or counts. Patient
characteristics were compared using the Chi-square test and
Fisher exact test for binary data, and nonparametric Mann–
Whitney U test (MWU) tests for continuous data. For all binary
data, logistic regression analysis was used, with results being
reported with odds ratios (ORs) and 95% conﬁdent intervals
(95% CI). Additionally, we adjusted our analysis for predeﬁned
possible confounders (model 1), such as demographics (ie, age
and gender), comorbidities (ie, cardiovascular diseases, renal
disease, and tumor), randomization, and vitamin D treatment.
The association between vitamin D levels and outcomes was
assessed in the overall population and furthermore in a subgroup
analysis for treated patients and untreated patients.
Evidence of effect modiﬁcation within these subgroups was
assessed by inclusion of interaction terms into the statistical
models. All statistical analyses were performed using the STATA
12.1 software (Stata Corp, College Station, TX). A P-value <.05
was considered statistically signiﬁcant.
3. Results
In our population of 828 malnourished inpatients, the prevalence
of vitamin D deﬁciency was 58.2% (n=482) including 188
patients (22.7%)who had severe deﬁciencywith a vitaminD level
of <25 nmol/L. Baseline characteristics are shown in Table 1,
stratiﬁed according to their vitamin D levels. Median age of the
population was 76 years and 45.7%were younger than 75 years.
About half of the population was female (n=403, 48.7%) and
vitamin D deﬁciency was more often found in males as compared
to females.
Figure 1. Patient classiﬁcation.
Merker et al. Medicine (2019) 98:48 www.md-journal.com
3
3.1. Association of vitamin D deﬁciency and primary and
secondary endpoints
Patients with vitamin D deﬁciency had an increased 180-day
mortality rate of 29.9% (144/482) compared to 23.1% (80/346)
in patients with no deﬁciency (Fig. 2A). This was also conﬁrmed
in a logistic regression analysis with an OR of 1.42 (95% CI
1.03–1.94, P= .03) for vitamin D deﬁciency (Table 2). Also, in a
subgroup analysis, we found a signiﬁcant association between
vitamin D deﬁciency and 180-day mortality in patients, who
never received vitamin D treatment (adjusted OR 1.63 [95% CI
1.01–2.62], P= .04) (Fig. 2B). In the subgroup of patients who
received vitamin D treatment, there was no signiﬁcant association
between vitamin D deﬁciency and 180 days mortality (adjusted
OR 0.98 [95% CI 0.60–1.61], P= .95) (Fig. 2C). This difference
in subgroup effects was also found to be strong in an interaction
analysis by vitamin D treatment (P for interaction .07 regarding
180-day mortality).
We also investigated associations of vitamin D deﬁciency and
different short-term outcomesmeasured at 30 days and long-term
outcomes measured at 180 days. Regarding short-term out-
comes, no signiﬁcant difference was found for 30-days mortality
between patients with and without vitamin D deﬁciency. We also
performed a subgroup analysis, where no signiﬁcant effects were
found (Table 3). Also, we did not ﬁnd a signiﬁcant difference in
decline of Barthel Index after 30-days, neither for reduced QoL
between vitamin D sufﬁcient and deﬁcient patients.
Table 1
Baseline characteristics overall and stratiﬁed by vitamin D status.
Characteristics Overall No vitamin D deﬁciency (≥50 nmol/L) Deﬁciency (<50 nmol/L) P-value
n (%) 828 346 (41.8) 482 (58.2)
Demographic characteristics
Age, yr (median, IQR) 76.0 (67.0, 83.0) 77.0 (67.0, 84.0) 75.0 (66.0, 82.0) .08
Male sex 425 (51.3%) 155 (44.8%) 270 (56.0%) .001
BMI, kg/m2 (median, IQR) 24.0 (21.0, 28.0) 24.0 (20.0, 27.0) 25.0 (21.0, 29.0) .008
BMI WHO
1 68 (8.3%) 27 (7.8%) 41 (8.5%) .001
2 419 (50.8%) 200 (58.1%) 219 (45.6%)
3 337 (40.9%) 117 (34.0%) 220 (45.8%)
NRS
3 229 (27.7%) 98 (28.3%) 131 (27.2%) .78
4 322 (38.9%) 137 (39.6%) 185 (38.4%)
5 277 (33.5%) 111 (32.1%) 166 (34.4%)
Main diagnosis
Infectious disease 219 (26.4%) 95 (27.5%) 124 (25.7%) .48
Cancer 181 (21.9%) 62 (17.9%) 119 (24.7%)
Cardiovascular disease 93 (11.2%) 45 (13.0%) 48 (10.0%)
Gastrointestinal disease 66 (8.0%) 28 (8.1%) 38 (7.9%)
Frailty 65 (7.9%) 31 (9.0%) 34 (7.1%)
Miscellaneous 59 (7.1%) 24 (6.9%) 35 (7.3%)
Pulmonary disease 52 (6.3%) 22 (6.4%) 30 (6.2%)
Renal disease 42 (5.1%) 17 (4.9%) 25 (5.2%)
Metabolic disorder 28 (3.4%) 10 (2.9%) 18 (3.7%)
Neurological disorder 23 (2.8%) 12 (3.5%) 11 (2.3%)
Comorbidities
Hypertension 488 (58.9%) 193 (55.8%) 295 (61.2%) .12
Cancer 290 (35.0%) 106 (30.6%) 184 (38.2%) .02
Chronic renal failure 288 (34.8%) 119 (34.4%) 169 (35.1%) .84
Cardiovascular disease 202 (24.4%) 87 (25.1%) 115 (23.9%) .67
Diabetes 198 (23.9%) 64 (18.5%) 134 (27.8%) .002
Chronic heart failure 148 (17.9%) 66 (19.1%) 82 (17.0%) .44
COPD 115 (13.9%) 47 (13.6%) 68 (14.1%) .83
PAOD 86 (10.4%) 31 (9.0%) 55 (11.4%) .25
Stroke 72 (8.7%) 34 (9.8%) 38 (7.9%) .33
Dementia 28 (3.4%) 14 (4.0%) 14 (2.9%) .37
Laboratory ﬁndings
Albumin median (IQR) 27.4 (23.1, 31.8) 27.6 (22.6, 31.9) 27.3 (23.3, 31.5) .99
Creatinin median (IQR) 88.0 (65.0, 133.0) 88.0 (67.0, 130.0) 87.5 (63.0, 136.0) .72
Calcium median (IQR) 2.1 (2.0, 2.2) 2.1 (2.0, 2.3) 2.1 (2.0, 2.2) .01
Phosphat median (IQR) 0.8 (0.5, 1.1) 0.8 (0.5, 1.1) 0.8 (0.6, 1.0) .84
Vitamin D on admission, median (IQR) 44.0 (26.1, 67.1) 72.6 (60.2, 87.6) 28.8 (19.4, 39.1) <.001
Clinical ﬁndings
Barthel index
Median (IQR) 85 (70, 95) 85 (70, 95) 90 (70, 95) .40
Functional impairment (≥10% decline) 530 (64%) 225 (65%) 305 (63.3%) .60
COPD = chronic obstructive pulmonary disease, IQR = interquartile range, NRS = nutritional risk screening 2002, PAOD = peripheral artery occlusive disease.
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Although patients with vitamin D deﬁciency had worse long-
term outcomes regarding functionality (Barthel index and QoL)
at 180 days, the overall statistical analysis did not show any
signiﬁcant association of vitamin D deﬁciency and adverse
outcomes in the overall population. The effects of vitamin D
deﬁciency were again more pronounced in patients not treated
with vitamin D, but were not statistically signiﬁcant.
3.2. Association of vitamin D deﬁciency and severe
deﬁciency on primary and secondary endpoints
To complement the analysis, we conducted all the calculations for
3 patient groups (no deﬁciency ≥50 nmol/L, deﬁciency ≥25
nmol–49.9 nmol/L, and severe deﬁciency <25nmol/L) (See
Supplemental Digital Content 2–4 for long-term outcomes,
short-term outcomes, and treatment as well as the baseline
characteristics in Digital Content 1 and patient classiﬁcation in
Digital Content 5, http://links.lww.com/MD/D408). Similar
to the initial analysis, 180-day mortality was increased for
vitamin D deﬁcient and severely deﬁcient patients (33.3% [98/
294] and 24.5% [46/188], P= .01). In a logistic regression
analysis, this association could only be conﬁrmed for vitamin D
deﬁcient patients with an OR of 1.66 (95% CI 1.17–2.36,
P= .004) and stayed robust after adjustment for model 1 (See
supplemental Digital Content 2). In a subgroup analysis, there
was also an association between vitamin D deﬁciency and 180-
day mortality in patients who never received vitamin D
treatment (adjusted OR 1.84 [95% CI 1.10–3.07], P= .02). We
could not ﬁnd such associations for patients with severe
vitamin D deﬁciency nor for patients who received vitamin D
treatment.
We also investigated the associations of vitamin D deﬁciency
and severe deﬁciency for other short and long-term outcomes. A
signiﬁcant long-term outcome was decline of Barthel index after
180 days (unadjusted OR 1.42 [95%CI 1.04–1.94], P= .02). In a
subgroup analysis, we could only ﬁnd a signiﬁcant association
between Barthel index decline and vitamin D deﬁcient patients,
adjusted OR 1.70 (95% CI 1.09–2.66, P= .01) but not for
severely deﬁcient patients.
Regarding short-term outcomes, there was only a signiﬁcant
association for 30-days mortality for vitamin D deﬁcient patients
who never received vitamin D treatment (unadjusted OR 2.17
[95% CI 1.01–4.68], P= .04). We could not ﬁnd any signiﬁcant
association between severely vitamin D deﬁcient patients and any
of our endpoints.
3.3. Effects of vitamin D treatment on outcomes
In an initial analysis, there was an inverse linear association of
vitamin D deﬁciency and mortality (Fig. 3A). After dividing the
population into 2 groups (“treated” and “untreated” patients)
vitamin D deﬁciency correlated with increased mortality for
patients with no vitamin D treatment. Compared to this
association, the graph did not show a correlating increased
mortality with low vitamin D levels on admission for patients
who received vitamin D treatment (Fig. 3B). This brought us to
the hypothesis that malnourished medical inpatients may beneﬁt
from vitamin D treatment in terms of long-term survival.
We; therefore, investigated the effects of vitamin D treatment
on clinical outcomes. Overall, there was no association of vitamin
D treatment with improved clinical outcomes (Table 4).
4. Discussion
The ﬁndings of our analysis regarding vitamin D deﬁciency in a
population of malnourished medical inpatients are 3-fold. First,
we found a high prevalence of vitamin D deﬁciency in this
vulnerable patient population of almost 60% with about 20%
being severely deﬁcient. Second, we found an association between
vitamin D deﬁciency and increased 180-day mortality. This
association remained robust in multivariate analysis in patients
with no treatment for vitamin D, but not in patients where
vitaminD treatment was established. Third, we also noted a trend
towards lower risk for mortality when vitamin D treatment was
established in the subgroup of patients with vitamin D deﬁciency.
Despite the high probability of vitamin D deﬁciency in patients
with malnutrition, there is lack of clinical data focusing on this
Figure 2. Correlation of vitamin D deﬁciency and survival in different patients
populations. (A) 180-d mortality in the overall population; (B) 180-d mortality in
untreated patients; (C) 180-d mortality in treated patients.
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particular group of patients. According to the National Health
and Nutrition Examination Survey (2005/2006), the prevalence
of vitamin D deﬁciency deﬁned as levels <50 nmol/L was 41.6%
for general adult persons.[22] According to a recent systematic
review on the topic,[13] the prevalence of vitamin D deﬁciency in
general medical inpatients was found to be around 50%using the
same cut-off. Our data show an even higher number for the
population of malnourished patients. This could be a conse-
quence of the severe illness and therefore patients not being able
to spend time outside. This results in reduced sun exposure and
eventually in vitamin D deﬁciency. Another explanation could be
the fact, that patients are malnourished and therefore are likely to
have a diet containing low vitamin D. To evade this potential
confounder, we adjusted our analysis to the randomization group
of the EFFORT trial (individual nutritional support or standard
nutrition). Our data provide evidence that a systematic screening
for vitamin D deﬁciency is warranted in the population of
malnourished patients although trials that prove vitamin D
treatment to reduce adverse outcomes in this population are still
lacking.
Similar to a recent study looking at general medical
inpatients[13] we also found an association of vitamin deﬁciency
and higher mortality at 180 days. This associationwas still robust
after multivariate adjustment in the subgroup of patients not
receiving vitamin D treatment while in treated patients no
harmful associations were found. In addition, we noted a trend of
lower risks among treated patients with vitamin D deﬁciency
compared to untreated patients. These ﬁndings from our
observational study do not prove that vitamin D supplementation
in this patient population would improve outcomes, but gives a
strong rational to perform trials investigating the effects of
vitamin D on outcomes in this patient population. Importantly, a
recently published large randomized, double-blind, placebo-
controlled study could not show, that high dose vitamin D (2000
IU/d) lowers the risk of cancer of any type and major
cardiovascular events in generally healthy persons (hazard ratio
[HR] 0.96 [95% CI 0.88–1.06]; P= .47 and HR 0.97 [95% CI
0.85–1.12]; P= .69, respectively).[23] Even though, this was a
very well-conducted trial, the results are hard to compare with
ours because of the 2 very diverse patient populations. The
Table 2
Long-term outcomes.
Characteristics 180-d mortality
Barthel index
decline (180 d)
QoL 180 d,
median (IQR)
LOS,
median (IQR)
Overall population
No vitamin D deﬁciency
(≥50 nmol/L) n=346
80 (23.1%) Decline: 151 (43.6%) 0.9 (0.8, 0.9) 8.0 (5.0, 13.0)
Deﬁciency (<50 nmol/L) n=482 144 (29.9%) Decline: 234 (48.5%) 0.9 (0.9, 0.9) 8.0 (5.0, 13.0)
P-value .03 .16 .005 .52
Unadjusted analysis
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.42 (1.03 to 1.94), P= .03 1.22 (0.92 to 1.61), P= .16 0.93 (0.41 to 2.09), P= .85 0.21 (1.09 to 0.67), P= .64
Fully adjusted
∗
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.27 (0.91 to 1.78), P= .16 1.09 (0.82 to 1.46), P= .55 0.87 (0.38 to 1.99), P= .74 0.32 (1.20 to 0.57), P= .48
Treated patients
No vitamin D deﬁciency
(≥50 nmol/L) n=157
41 (26.1%) Decline: 67 (42.7%) 0.89 (0.79, 0.89) 8.0 (5.0, 14.0)
Deﬁciency (<50 nmol/L) n=221 59 (26.7%) Decline: 96 (43.4%) 0.89 (0.81, 0.89) 8.0 (6.0, 14.0)
P-value .90 .88 .30 .64
Unadjusted analysis
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.03 (0.65 to 1.64), P= .89 1.03 (0.68 to 1.56), P= .88 1.06 (0.23 to 4.79), P= .94 0.07 (1.45 to 1.30), P= .91
Fully adjusted†
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference Reference
Deﬁciency (<50 nmol/L) 0.98 (0.60 to 1.61), P= .95 0.97 (0.62 to 1.49), P= .87 0.89 (0.19 to 4.13), P= .88 0.41 (1.79 to 0.96), P= .55
Untreated patients
No vitamin D deﬁciency
(≥50 nmol/L) n=189
39 (20.6%) Decline: 84 (44.4%) 0.9 (0.8, 0.9) 8.0 (6.0, 12.0)
Deﬁciency (<50 nmol/L) n=261 85 (32.6%) Decline: 138 (52.9%) 0.9 (0.9, 1.0) 7.0 (5.0, 12.0)
P-value .005 .07 .006 .13
Unadjusted analysis
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.86 (1.20 to 2.88), P= .006 1.40 (0.96 to 2.04), P= .07 0.87 (0.33 to 2.30), P= .78 -0.33 (-1.46 to 0.80), P= .56
Fully adjusted†
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.63 (1.01 to 2.62), P= .04 1.29 (0.86 to 1.92), P= .21 0.86 (0.32 to 2.30), P= .75 0.40 (1.56 to 0.75), P= .49
Interaction
P for interaction .07 .277 .198 .775
IQR= interquartile range.
∗
Fully adjusted analysis for demographics, comorbidities, randomization, and substitution.
† Fully adjusted analysis for demographics, randomization, and comorbidities.
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investigated patients in the study from Manson et al included
young and healthy adults, mean age 67.1 years and with no
history of cardiovascular diseases or cancer. Our study
population was malnourished inpatients with several comorbid-
ities andmean age is 76 years.We; therefore, think the conclusion
of this trial cannot be transferred to malnourished medical
inpatients. Conducting further trials focusing on vitamin D
deﬁciency and potential beneﬁt from treatment in malnourished
medical inpatients is warranted.
Another recently published systematic review focused on the
effect of vitamin D supplementation on fractures, falls and bone
density.[24] It showed no effect of vitamin D supplementation to
prevent fractures or falls or has signiﬁcant effects on bonemineral
density. They have analyzed 81 randomized controlled trials of
vitamin D supplements that reported falls, fractures or bone
mineral density as an outcome. Conversely, Neelemaat et al[25]
could show a decrease in falls in malnourished patients who
received oral nutritional intervention. The intervention group
received energy and protein-enriched diet with vitamin D
supplementation during the in-hospital period and showed a
decreased number of individuals with falls and fall incidents
compared to the control group. This association was not
signiﬁcant anymore, when they looked at vitamin D deﬁcient
patients only. This leads to the assumption that the positive effect
is most likely due to the combined intervention and not only due
to vitamin D supplementation. The inconsistent recommenda-
tions of vitamin D supplementation to reduce falls, fractures, and
mineral bone density might explain why some guidelines
recommend vitamin D supplementation and others do not.
Clearly, more studies are needed to conﬁrm our ﬁndings and to
establish whether vitamin D treatment has positive effects in the
population of malnourished inpatients.
Our study has several strengths, including a large and well-
characterized population of malnourished medical inpatients
with assessment of different outcomes and rigorously adjusted
analyses based on a prespeciﬁed analysis plan. Still, we are aware
of several limitations. Most importantly, patients were not
randomized to receive vitamin D treatment or not and there is
thus possible confounding by indication (see Appendix Table 6,
http://links.lww.com/MD/D407). We classiﬁed patients as
“treated” and “untreated” according to the prescribed vitamin
D supplement on hospital admission. Because most patients that
had vitamin D supplements on admission were discharged again
with a vitamin D order, we did not further look into subgroups
based on timing of vitamin D treatment. Also, we did not have
any information about compliance with vitamin D treatment
before and after hospitalization. Furthermore, vitamin D levels
were measured only in 828 patients out of 2088 malnourished
Table 3
Short-term outcomes.
Characteristics 30-d mortality Barthel index decline (30 d) QoL 30 d, median (IQR)
Overall population
No vitamin D deﬁciency (≥50 nmol/L) n=346 26 (7.5%) Decline: 39 (11.3%) 0.9 (0.5, 1.0)
Deﬁciency (<50 nmol/L) n=482 45 (9.3%) Decline: 67 (13.9%) 0.9 (0.4, 1.0)
P-value .36 .26 .82
Unadjusted analysis
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.27 (0.77 to 2.10), P= .35 1.27 (0.83 to 1.94), P= .26 0.72 (0.48 to 1.07), P= .10
Fully adjusted
∗
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.14 (0.68 to 1.90), P= .62 1.18 (0.77 to 1.81), P= .45 0.77 (0.51 to 1.17), P= .21
Treated patients
No vitamin D deﬁciency (≥50 nmol/L) n=157 15 (9.6%) Decline: 21 (13.4%) 0.8 (0.5, 0.9)
Deﬁciency (<50 nmol/L) n=221 18 (8.1%) Decline: 30 (13.6%) 0.9 (0.4, 1.0)
P-value .63 .96 .80
Unadjusted analysis
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference
Deﬁciency (<50 nmol/L) 0.84 (0.41 to 1.72), P= .63 1.02 (0.56 to 1.85), P= .95 0.82 (0.46 to 1.47), P= .50
Fully adjusted†
Normal vitamin D status (≥50 nmol/L) Reference Reference Reference
Deﬁciency (<50 nmol/L) 0.86 (0.41 to 1.79), P= .68 1.07 (0.58 to 1.98), P= .83 0.78 (0.43 to 1.43), P= .42
Untreated patients
No vitamin D deﬁciency (≥50 nmol/L) n=189 11 (5.8%) Decline: 18 (9.5%) 0.9 (0.5, 1.0)
Deﬁciency (<50 nmol/L) n=261 27 (10.3%) Decline: 37 (14.2%) 0.9 (0.4, 1.0)
P-value .08 .14 .95
Unadjusted analysis
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.87 (0.90 to 3.87), P= .09 1.57 (0.86 to 2.85), P= .13 0.63 (0.36 to 1.11), P= .11
Fully adjusted†
No vitamin D deﬁciency (≥50 nmol/L) Reference Reference Reference
Deﬁciency (<50 nmol/L) 1.53 (0.72 to 3.25), P= .27 1.32 (0.71 to 2.45), P= .37 0.77 (0.43 to 1.39), P= .38
Interaction
P for interaction .12 .34 .83
IQR= interquartile range.
∗
Fully adjusted analysis for demographics, comorbidities, randomization, and substitution.
† Fully adjusted analysis for demographics, randomization, and comorbidities.
Merker et al. Medicine (2019) 98:48 www.md-journal.com
7
patients, which may limit generalizability. Finally, this is an
observational study and the decision about vitamin D treatment
in our study was up to the treating physician team. Thus our data
do not prove causality of vitamin D deﬁciency in malnourished
patients and adverse clinical outcomes. There is risk for
unmeasured factors, such as dietary intake, sun exposure, genetic
variants, and lifestyles, which could interfere with our analysis.
To close this gap, interventional studies are needed to verify that
vitamin D deﬁcient, malnourished patients show better outcomes
after substitution.
5. Conclusion
In conclusion, vitamin D deﬁciency is highly prevalent in
the population of malnourished inpatients and is negatively
associated with long-term mortality particularly when patients
are not receiving vitamin D treatment. Interventional trials
should investigate the potential beneﬁt from vitamin D
screening and treatment in malnourished patients with
deﬁciency.
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